Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors

Core Insights - Onconetix, Inc. has appointed David White as Chief Executive Officer and Sammy Dorf to its Board of Directors, reflecting a strategic move to enhance leadership as the company prepares for the acquisition of Realbotix LLC, a developer of AI-powered humanoid robots [1][2][3] Leadership Appointments - David White brings over 30 years of executive experience, having held CEO, CFO, and COO roles in various sectors including transportation and healthcare. He has served on multiple public company boards and holds a CPA designation [2][4] - Sammy Dorf is an entrepreneur and investor with a strong background in capital markets and corporate governance. He co-founded Verano Holdings Corp. and has held significant roles in public companies, contributing to their strategic transformations [3][4] Acquisition of Realbotix - The acquisition of Realbotix is seen as a transformative opportunity for Onconetix, positioning the company at the intersection of AI and humanoid robotics, which is a rapidly evolving sector [3][5] - The leadership team believes that the acquisition will create significant value for shareholders and is focused on executing the transaction successfully [5][6] Company Background - Onconetix, Inc. is a commercial-stage biotechnology company specializing in innovative oncology solutions, including Proclarix®, an in vitro diagnostic test for prostate cancer [6] - Realbotix LLC, the target of the acquisition, develops AI-powered humanoid robots designed for human interaction, with patented technologies enabling lifelike expressions and social engagement [7]